Support teaching, research, and patient care.
Sanjiv Narayan is Professor of Medicine, Director of the Stanford NIH T32 CHIP (Computational medicine in the Heart: Integrated Program HL166155), and is Co-Founder of the Stanford Arrhythmia Center. Narayan directs the Computational Arrhythmia Research Lab (CARL), that operates at the intersection of cardiovascular medicine, bioengineering, and data science. CARL pioneered computational mapping of 'chaotic' heart rhythm disturbances (arrhythmias), targeting mechanistic drivers for atrial and ventricular fibrillation (AF, VF) using machine learning and computational models. Dr. Narayan’s laboratory works with collaborators worldwide. Dr. Narayan received the Distinguished Scientist Award of the Heart Rhythm Society (2022), and several other prizes including "Top Doctor" (Castle Connolly 2017-present). Our talented trainees have won an average of 2-3 prizes or grants every year since 2003.PersonalDr. Narayan was born in Aylesbury, Buckinghamshire, England, then his parents Prakash and Kamalini moved to Birmingham UK. Dr Narayan trained in medicine (MB, ChB 1987) and software engineering focused on neural networks (MSc, 1990) in Birmingham UK with further training in Information and Data Science at the University of California, Berkeley (2022-). He gained membership (MRCP, 1990) and fellowship (FRCP,) of the Royal College of Physicians of London. At the Lab of Neuroimaging of Dr. Arthur Toga, PhD at UCLA, he developed optical mapping and image processing software to study somatosensory cortex (Research MD, 1995). He trained in Internal medicine at Harvard/Mount Auburn Hospital under Dr. Charles Hatem, and Cardiology/EP (with computational research) at Washington University/Barnes hospital under Drs Michael Cain, Joseph Smith and Bruce Lindsay. Dr. Narayan is a devoted family man, and he and his wife Sujata Narayan (Family Practice, Stanford) have 3 children. Together, they enjoy music, history, politics, swimming, biking, skiing and travel.Funding Disclosures:CARL is grateful to the Laurie C. McGrath Foundation, and to the National Institutes of Health for continuous support since 2001. Specific support has been via grants HL70529 and HL162260 for ventricular arrhythmias, and HL103800, HL83359, HL122384, HL149134, and several SBIR grants for atrial arrhythmias. Our fellows have won funding by the Fulbright Foundation, NIH, American College of Cardiology, American Heart Association, Heart Rhythm Society, and British Heart Foundation. The lab has co-invented intellectual property owned by University of California Regents and Stanford University, of which Focal Impulse and Rotor Mapping (FIRM) was licensed to a start-up founded by Dr. Narayan (Topera), which was acquired by Abbott Laboratories in 2014.
Dr. Narayan directs the Computational Arrhythmia Research Laboratory, whose goal is to define the mechanisms underlying complex human heart rhythm disorders, to develop bioengineering-focused solutions to improve therapy that will be tested in clinical trials. The laboratory has been funded continuously since 2001 by the National Institutes of Health, AHA and ACC, and interlinks a disease-focused group of clinicians, computational physicists, bioengineers and trialists.
Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF
This prospective randomized study will assess the safety and efficacy of FIRM-guided ablation
(FIRM+PVI) compared to pulmonary vein isolation (PVI) without FIRM, for the treatment of
symptomatic atrial fibrillation.
View full details
Ablation of Ventricular Fibrillation by Accurate Targeting of Arrhythmogenic Regions (AVATAR)
This study will test the hypothesis that many human heart rhythm disorders are caused by
small localized sources, where brief ablation may successfully eliminate the heart rhythm
The Dynamics of Human Atrial Fibrillation
The study is conducted in patients with atrial fibrillation undergoing clinically prescribed
ablation. The study hypothesis is that ablation at specific sites that are identified to
'drive' the atrial fibrillation may improve the success of the ablation procedure.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kathleen Mills, (858) 449-3252.